ACS Sensors
Cure8 research brief
Why This Matters
This study describes a prototype smart oral capsule that senses colonic inflammation and releases budesonide locally, which could reduce systemic exposure and allow on‑demand, lesion‑specific treatment if translated to humans.
Who Should Pay Attention
Researchers, clinicians in IBD therapeutics and drug-delivery, and patients interested in emerging targeted treatment technologies.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This paper describes an experimental ingestible (oral) capsule designed to sense local signals of colonic inflammation and release a contained drug when thresholds are reached.
The capsule uses a dual-layer shell responsive to pH and matrix metalloproteinases to target the colon, integrated sensors that detect TNF‑α, pH, and sodium, and budesonide-loaded nanoparticles that are triggered by reactive oxygen species to release drug in inflamed tissue.
In animal models (cell studies, DSS mouse colitis, and tests in rats) the device produced on‑demand drug release and reduced inflammation after a single intervention according to the authors. The report presents preclinical proof‑of‑concept rather than clinical data.
This is an early-stage, device-plus-drug research platform that illustrates a closed‑loop "sense–decide–act" approach; it is not an available treatment and has not been tested in humans.
Keep In Mind
Results are preclinical (cell lines, DSS mouse colitis, and rat experiments) and reflect a proof‑of‑concept device; human testing and regulatory steps are not reported.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationACS Sensors
PublisherAmerican Chemical Society (ACS)
AuthorsWen Pan, Jie Fu, Shouzhe Deng +8 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedOct 14, 2026, 12:00 AM
Content availableJournal abstract
Funding disclosed by the source: National Key Research and Development Program of China, award 2022YFF1202700
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Colon-targeted oral delivery of melatonin for regulating macrophage activity and intestinal barrier in ulcerative colitis.
Targeted oral delivery of melatonin could reduce inflammation and help repair the intestinal barrier in UC by acting on macrophages and epithelial cells. If translated to humans, this approach might offer a locally...
Orally administered 5-ASA-loaded full-active nanodrug for targeted therapy of inflammatory bowel disease
The paper describes a new nanodelivery method that improves targeted delivery of 5‑ASA in preclinical models, which could eventually address limitations of oral mesalazine formulations for colonic inflammation.
Quaternized chitosan-based double-network hydrogel for oral precise delivery of Sinapic acid in ulcerative colitis therapy.
The study describes a novel hydrogel designed to deliver sinapic acid directly to the inflamed colon and release drug in response to a reducing environment—an approach that could improve targeted oral therapies for...